Jubilant Draximage Inc., a subsidiary of company's wholly owned subsidiary Jubilant Pharma Limited, announced an investment of US$ 50 million to expand its PET radiopharmacy network by adding six (6) PET radiopharmacies in strategic locations throughout the United States. The new PET radiopharmacies shall be operational by Financial Year 2027-28.
Health Canada Issues Recall of Jubilant DraxImage Inc`s DRAXIMAGE MDP
Enforcement Report - Week of July 20, 2022
Enforcement Report - Week of April 1, 2020
Jubilant DraxImage Inc., a wholly owned subsidiary of Jubilant Pharma Limited, is pleased to announce the receipt of the CE Mark certificate for its state-of-the-art RUBY Rubidium Elution System (RbES) and the proprietary RUBY consumable accessories dedicated for use with their RUBY-FILL® (Rubidium Rb82 Generator). This certificate allows the device to be distributed into the European Economic Area (EEA).
Ruby-Fill® (Rubidium-82): Bracco Diagnostics v. Jubilant Draximage
“The company’s wholly own subsidiary Jubilant Pharma, through one of its units Jubilant DraxImage Inc. Montreal Canada (JDI), has signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans to be supplied by JDI over a period of 39 months effective from January 2017,” Jubilant Life Sciences said in a release.
Drug firm Jubilant Life SciencesBSE 2.00 % today said its subsidiary Jubilant DraxImage Inc has signed a term sheet with Australia's Cyclopharm for exclusive licence to market Technegas in the US.